Why It Matters
A key federal advisory panel has unanimously endorsed a new mRNA-based influenza vaccine for adults 50 and older, marking the first new vaccine application review by the committee since 2023. The decision comes as the United States recorded some of its most severe flu season numbers in years, with broad implications for how quickly future vaccines can be developed and deployed.
What Happened
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, known as VRBPAC, voted nine to zero to recommend Moderna’s mRNA influenza vaccine, branded mFlusiva, following six and a half hours of review. The committee found no major safety issues or deficiencies in the application.
The path to the review was not without turbulence. In February, the FDA initially declined to review Moderna’s application before reversing that decision two weeks later. The committee ultimately moved forward with a full evaluation.
Dr. Anna Durbin, one of the committee members, emphasized the integrity of the process. “There were no shortcuts taken,” she said. “There was a full efficacy evaluation done per standard FDA guidance.”
The vaccine works by delivering microscopic doses of mRNA corresponding to three to four influenza strains, prompting the immune system to produce a broader and longer-lasting antibody response compared to traditional flu shots. Clinical trial data, published in the New England Journal of Medicine and Nature Immunology, showed the vaccine produced antibodies capable of recognizing a wider range of flu strains based on detailed analysis of 75 trial participants.
By the Numbers
The 2025–2026 flu season underscored the stakes involved. The U.S. recorded approximately 32 million influenza cases, 390,000 hospitalizations, and 24,000 deaths during that period. Despite available vaccines, roughly 85 percent of those eligible were not fully vaccinated against influenza.
Since 2020, more than 6 billion doses of mRNA vaccines have been administered globally, providing a substantial safety record for the platform. The VRBPAC recommendation also highlights a significant manufacturing advantage: mRNA technology could reduce the time needed to develop a strain-specific vaccine from the current six-month window down to just two to three months, which would be particularly valuable during a rapid outbreak or pandemic scenario.
The committee’s vote was its first on a new vaccine application in roughly three years, since 2023.
Zoom Out
The recommendation arrives during a period of scrutiny over federal vaccine policy. Earlier this year, the Department of Health and Human Services pulled approximately $500 million in mRNA vaccine development contracts, creating uncertainty about the technology’s future within government health programs. The unanimous committee vote is being read by some health experts as a signal that established scientific review processes remain intact.
Dr. Paul Offit, a vaccine researcher and VRBPAC member, described the proceeding as a return to normalcy. “It’s such a breath of fresh air,” he said, referencing the turbulent climate surrounding vaccine policy in recent years.
More broadly, the development reflects a wider trend of mRNA technology moving beyond its COVID-19 applications. Researchers have pursued mRNA-based approaches for influenza, respiratory syncytial virus, and other infectious diseases, citing the platform’s speed and adaptability as key advantages over conventional vaccine manufacturing methods.
What’s Next
The VRBPAC recommendation is advisory, meaning the FDA will now conduct its own review before issuing a final decision on whether to approve mFlusiva for public use. If approved, the vaccine would initially be authorized for adults 50 and older. A broader rollout or expanded age authorization would require additional regulatory steps. No timeline for the FDA’s final determination has been publicly announced.
The outcome of the FDA’s decision will be closely watched given the combination of strong flu season data, the unanimous committee vote, and the ongoing national debate over vaccine policy under the current administration.